Avantor (AVTR) Financial Analysis & Valuation | Quarter Chart
Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and... more
Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and go... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $11.69B | Exchange | NYSE |
| Sector | Healthcare | Industry | Medical - Instruments & Supplies |
| Country | US | CEO | Emmanuel Ligner |
| IPO Date | 2019-05-17 | CAGR | 26.25% |
| Employees | 13,500 | Website | www.avantorsciences.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 0.02% | Total Yield | 0.02% |
AVTR chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $8.57B | P/E | 20.34 | Forward P/E | 19.76 | PEG | — |
| P/S | 65.82 | P/B | 78.53 | P/CF | 990.86 | P/FCF | 1516.75 |
| Sales | $6.56B | Sales 1Y | -1.57% | Sales 3Y | -8.57% | Sales 5Y | -6.8% |
| EPS | $0.85 | EPS 1Y | -183.59% | EPS 3Y | -233.21% | EPS 5Y | -286.49% |
| Sales QoQ | 7.01% | EPS QoQ | -5.81% | Sales QoQ Avg | 0.25% | EPS QoQ Avg | -331.62% |
| Gross Margin | 31.83% | Operating Margin | -4.35% | Profit Margin | -8.81% | ROCE | -2.8% |
| ROA | -5% | ROE | -10% | Altman Z Score | 1.77 | Piotroski Score | 6 |
| Current Ratio | 1.78 | Quick Ratio | 1.18 | Cash Ratio | 0.22 | Op. CF Ratio | 0.01 |
| Debt/Equity | 0.01 | Debt/Assets | 0 | Lt Debt/Equity | — | Lt Debt/Cap. | — |
| Intrst Cov. | -1.6 | Inventory Turnover | 5.4 | Asset Turnover | 0.57 | Receivables Turnover | 5.76 |
| Enterprise Value | $8.57B | P/E Ratio | 20.34 |
| Forward P/E | 19.76 | PEG Ratio | — |
| P/S Ratio | 65.82 | P/B Ratio | 78.53 |
| P/CF Ratio | 990.86 | P/FCF Ratio | 1516.75 |
| EPS | $0.85 | EPS Growth 1Y | -183.59% |
| EPS Growth 3Y | -233.21% | EPS Growth 5Y | -286.49% |
| Revenue Growth 1Y | -1.57% | Gross Margin | 31.83% |
| Operating Margin | -4.35% | Profit Margin | -8.81% |
| ROE | -10% | ROA | -5% |
| ROCE | -2.8% | Current Ratio | 1.78 |
| Quick Ratio | 1.18 | Cash Ratio | 0.22 |
| Debt/Equity | 0.01 | Interest Coverage | -1.6 |
| Altman Z Score | 1.77 | Piotroski Score | 6 |
Avantor (AVTR) valuation & financials
Avantor (AVTR) has a market capitalization of $11.69B and trades at a price-to-earnings ratio of 20.3. It operates in the Healthcare sector (Medical - Instruments & Supplies).
Avantor's revenue grew -1.6% over the last year.
Avantor's next earnings report is scheduled for October 28, 2026 before market open (provider scheduled date); analysts estimate EPS of $0.21. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)